A Study of CX157 (TriRima) for the Treatment of Depression
Public ClinicalTrials.gov record NCT00739908. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 (TriRima) 60mg Three Times a Day (TID) in Subjects With Major Depressive Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of CX157 in these subjects.
Study identification
- NCT ID
- NCT00739908
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 285 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2008
- Primary completion
- Jun 30, 2009
- Completion
- Jun 30, 2009
- Last update posted
- Jun 26, 2012
2008 – 2009
United States locations
- U.S. sites
- 14
- U.S. states
- 14
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham Research Group | Birmingham | Alabama | 35216 | — |
| Southwestern Research, Inc. | Beverly Hills | California | — | — |
| The George Washington University | Washington D.C. | District of Columbia | — | — |
| Irving S. Kolin, M.D. | Winter Park | Florida | 32789 | — |
| Midwest Center for Neurobehavioral Medicine | Oakbrook Terrace | Illinois | — | — |
| Capital Clinical Research Associates | Rockville | Maryland | — | — |
| McLean Hospital | Belmont | Massachusetts | — | — |
| CRI Worldwide, LLC | Clementon | New Jersey | — | — |
| Fieve Clinical Services | New York | New York | — | — |
| Richard H. Weisler, M.D., P.A. | Raleigh | North Carolina | — | — |
| University of Pennsylvania School of Medicine | Philadelphia | Pennsylvania | — | — |
| FutureSearch Trials | Austin | Texas | 78756 | — |
| Summit Research Network (Seattle), LLC | Seattle | Washington | — | — |
| Northbrooke Research Center | Brown Deer | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00739908, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2012 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00739908 live on ClinicalTrials.gov.